Home › Funds › Davern Capital Partners, LP › IONS

Davern Capital Partners, LP position in IONS

IONIS PHARMACEUTICALS INC · Health Care

Davern Capital Partners, LP reported holding 1,087,142 shares of IONS (IONIS PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$48.5M, representing 9.44% of its reported portfolio and ranking #5 among its reported holdings. Davern Capital Partners, LP has disclosed IONS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)1.09M sh
Reported value held$48.54M
Portfolio Weight9.44%
First reportedQ4 2025
Last changeAdd
Updated2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

How Davern Capital Partners, LP's IONS position evolved

Davern Capital Partners, LP first disclosed a stake in IONS in Q4 2025 at 238,477 shares (US$18.9M). The position peaked in Q2 2026 at 798,709 shares, worth US$63.3M. Across 4 filings, Davern Capital Partners, LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,087,142 shares valued at US$48.5M — an increase of 288,433 shares quarter over quarter.. Notable position changes include a 62% increase in Q1 2026 (shares rose 6% over the following quarter), a 106% increase in Q2 2026 (shares fell 44% over the following quarter), a 36% increase in Q3 2026 (shares fell 37% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 238.48K $18.87M New
Q1 2026 386.90K $29.05M Add
Q2 2026 798.71K $63.33M Add
Q3 2026 1.09M $48.54M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IONS and 13F data

IONS (IONIS PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in IONS — the largest reported positions include Two Sigma Investments (US$495.7M), TWO SIGMA ADVISERS, LP (US$241.5M), Tweedy, Browne Co LLC (US$180.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IONS

All IONS fund holders →

FAQ

How long has Davern Capital Partners, LP held IONS?

Davern Capital Partners, LP has disclosed IONS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Davern Capital Partners, LP's current position in IONS?

As of Q3 2026, Davern Capital Partners, LP holds 1.09M shares of IONS (IONIS PHARMACEUTICALS INC), valued at $48.54M, representing 9.44% of its reported portfolio and ranking #5.

Has Davern Capital Partners, LP been buying or selling IONS?

In the latest 13F filing (Q3 2026), Davern Capital Partners, LP increased its position in IONS. The position peaked in Q2 2026 at 798.71K shares.

Which other funds hold IONS?

Other major institutional holders of IONS include Two Sigma Investments, TWO SIGMA ADVISERS, LP, Tweedy, Browne Co LLC, among 40 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.